The Relative Strength (RS) Rating for Axsome Therapeutics jumped into a new percentile Monday, with an increase from 79 to 82.
Risk Management In The Stock Market: How Much Money To Invest Now
This unique rating identifies technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against that of all other stocks.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains often have an RS Rating of above 80 as they launch their biggest price moves.
While the stock is not near an ideal buy point right now, see if it goes on to form and break out from a proper base.
The company showed 0% EPS growth in its most recent report, while sales growth came in at 62%.
Axsome Therapeutics holds the No. 91 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ADMA Biologics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
